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Congenital disorders of glycosylation (CDGs) form a genetically and clinically heterogeneous group of diseases with aberrant protein
glycosylation as a hallmark. A subgroup of CDGs can be attributed to disturbedGolgi homeostasis. However, identification of pathogenic
variants is seriously complicated by the large number of proteins involved. As part of a strategy to identify human homologs of yeast pro-
teins that are known to be involved in Golgi homeostasis, we identified uncharacterized transmembrane protein 199 (TMEM199, previ-
ously calledC17orf32) as ahumanhomologof yeastV-ATPase assembly factorVph2p (also knownasVma12p). Subsequently,we analyzed
raw exome-sequencing data from families affected by genetically unsolvedCDGs and identified four individuals with differentmutations
in TMEM199. The adolescent individuals presented with a mild phenotype of hepatic steatosis, elevated aminotransferases and alkaline
phosphatase, and hypercholesterolemia, as well as low serum ceruloplasmin. Affected individuals showed abnormal N- and mucin-type
O-glycosylation, and mass spectrometry indicated reduced incorporation of galactose and sialic acid, as seen in other Golgi homeostasis
defects.Metabolic labeling of sialic acids in fibroblasts confirmed deficient Golgi glycosylation, whichwas restored by lentiviral transduc-
tion with wild-type TMEM199. V5-tagged TMEM199 localized with ERGIC and COPImarkers in HeLa cells, and electronmicroscopy of a
liver biopsy showed dilated organelles suggestive of the endoplasmic reticulum and Golgi apparatus. In conclusion, we have identified
TMEM199 as a protein involved in Golgi homeostasis and show that TMEM199 deficiency results in a hepatic phenotype with abnormal
glycosylation.The introduction of exome sequencing in genetics has had
an enormous impact on the identification of Mendelian
disorders.1 However, genetic variants can appear to be
falsely positive, and a considerable percentage of cases still
remains genetically unsolved.2,3 The availability of func-
tional data improves candidate gene selection in the case
of well-known biochemical pathways.4 However, this is
more complicated for complex pathways with many un-
known proteins, such as the secretory pathway, which is
composed of the endoplasmic reticulum (ER), the Golgi
apparatus, and secretory vesicles. Multiple monogenic dis-
orders have been associated with abnormal membrane
trafficking, resulting in diverse clinical phenotypes.5 Pro-
tein glycosylation also occurs in the secretory pathway: as-
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Congenital disorders of glycosylation (CDGs) form a group
of >100 monogenic diseases affecting glycosylation.7 In a
subgroup of CDGs, abnormal glycosylation of serum
proteins is caused by a disturbance of Golgi homeostasis.
Examples are abnormal retrograde Golgi transport of
glycosyltransferases (conserved oligomeric Golgi [COG]
complex defects), abnormal ion transport (TMEM165 defi-
ciency [MIM: 614727]), and abnormal Golgi pH regulation
(ATP6V0A2 deficiency [MIM: 219200]).8–12 ATP6V0A2 is
a subunit of the vacuolar Hþ-ATPase (V-ATPase), the pro-
ton pump responsible for acidification of the secretory
pathway, among other functions.13
Identification of more genes involved in this emerging
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Figure 1. TMEM199 Domain Structure, Genetic Variants, and Conservation
Schematic representation of the intron-exon structure of TMEM199 and the encoded protein. The mutations and substitutions within
the different families are indicated by red lines. The yellow region indicates the conserved Vma12 domain ([Pfam: PF11712] amino acids
78–203). The two predicted transmembrane regions (Tm1 and Tm2) are indicated by a blue box.biological insights into organelle homeostasis and vesicu-
lar transport. However, this is challenging given the
large number of proteins involved, many of these with
unknown functions. We set out to identify human
Golgi-related proteins by using a bioinformatics search
for human homologs of yeast proteins with a known
role in ER-to-Golgi transport and/or Golgi glycosylation,
including the V-ATPase. Yeast-to-human comparative
genomics via a profile-based method, Position-Specific
Iterated (PSI)-BLAST,14 revealed transmembrane protein
199 (TMEM199, also known as C17orf32 [GenBank:
NP_689677.1]) as a human homolog for yeast Vph2p
(also known as Vma12p [GenBank: NP_012803]). Both
proteins were identified as each other’s best hit in
the third iteration with an E-value of 3e-08 and a
reciprocal E-value of 6e-18, suggesting that both proteins
are orthologs.15 Vph2p localizes to the ER and has
a confirmed role as a V-ATPase assembly factor.16,17 Sub-
sequently, we searched for TMEM199 mutations in indi-
viduals with genetically unsolved Golgi glycosylation
defects.
DNA of individuals F1-II2, F1-II3 and F2-II2 was isolated
from fibroblasts and subjected to whole-exome sequencing
as described.18 All individuals, or their legal representa-
tives, participating in this study provided informed con-
sent, and all biological materials were obtained in accor-
dance with the Declaration of Helsinki.The AmericOur in-house bioinformatics pipeline was used to anno-
tate called variants and indels.19 A frequency of >0.2% in
an in-house database of over 1,300 exomes was set for
exclusion of variants. We searched for non-synonymous
variants located in exons and canonical splice sites. As
quality criteria, we only included variants called more
than five times and with a frequency of more than 20%
for heterozygous variants and 80% for homozygous vari-
ants. According to a model of autosomal-recessive inheri-
tance, no obvious candidate genes could be identified.
For brothers F1-II2 and F1-II3 from family F1, previous
homozygosity mapping and targeted chip-based gene
sequencing of all genes in the largest homozygous inter-
vals did not reveal a clear candidate gene either. Inspection
of the raw exome-sequencing data of both brothers was
carried out with the Integrative Genomics Viewer (IGV,
v.2.3.14, Broad Institute). Zooming in on all TMEM199
exons (GenBank: NM_152464.2) revealed a missense mu-
tation, c.20C>A (p.Ala7Glu), in exon 1 (Figure 1). This
variant had a sequence depth of three reads in one sibling
and no coverage for the other affected sibling. Sanger
sequencing confirmed the missense mutation to be homo-
zygous in DNA from both affected siblings and heterozy-
gous in both parents. The mutation was absent from a
healthy sister, thereby showing complete segregation of
the mutation in the family, in agreement with auto-
somal-recessive inheritance (Figure 2A).an Journal of Human Genetics 98, 322–330, February 4, 2016 323
Figure 2. TMEM199 Mutations,
TMEM199 Levels, and Liver Ultrastructure
(A) Pedigrees and sequence profiles of
TMEM199 mutations in families F1 to F3.
(B) Sequencing of TMEM199 cDNA from
individual F2-II2 showed homozygosity
for the c.40G>C missense mutation. The
insert shows the splice site prediction ac-
cording to Alamut v.2.5.1 (Interactive Bio-
software), indicating a new splice site one
nucleotide downstream.
(C) Western blot analysis of TMEM199
levels was performed on fibroblasts from
healthy control individuals and affected
individuals with anti-TMEM199 antibody
(1:250, Sigma, #HPA027051) (left).
TMEM199-V5 was overexpressed in HeLa
cells and the Western blot incubated with
anti-TMEM199 antibody (right). As a pro-
tein loading control, the same blot was
incubated with mouse anti-GAPDH anti-
body (1:2,500, Calbiochem, #CB1001).
(D–F) Transmission electron microscopy of
liver tissue from individual F2-II2.
(D) Focally, lipid vacuoles were present in
the paranuclear area (asterisk).
(E) Enlarged hepatocytes show diffuse and
severe vacuolization most likely derived
from rough ER, smooth ER, and/or Golgi
apparatus.
(F) Mitochondria featured fragmented
cristae and an altered inner matrix appear-
ing as granulo-filamentousmaterial. Some-
times electron-dense crystal-like structures
were included in the mitochondria
(arrow).For individual F2-II2, standard filtering of the whole-
exome sequencing data indicated a heterozygous variant
in the splice acceptor site of TMEM199 exon 4 (c.376-
1G>A) (Figure 1). The raw exome-sequencing data revealed
an uncalled heterozygous missense variant in exon 1
(c.40G>C [p.Ala14Pro]). Sequencing of parental DNA
showedheterozygosity for the c.40G>Cmutation in the fa-
ther and heterozygosity for the c.376-1G>A mutation in
the mother. A healthy sister did not show any of these mu-
tations (Figure 2A). To further study the effect of the splice
site mutation, we extracted mRNA from skin fibroblasts,
synthesized cDNA, and sequenced it by Sanger sequencing.
The resulting cDNA sequence showed the c.40G>C variant
in homozygous form (Figure 2B), suggesting nonsense
mediated decay of mRNA transcribed from the allele with
the splice site mutation. Splice site prediction software
(Alamut Visual v.2.5.1, Interactive Biosoftware) predicted
the mutation to induce a stop codon 14 positions down-
stream by skipping one nucleotide (Figure 2B).
Sanger sequencing of TMEM199 in a cohort of individ-
uals with genetically unsolved Golgi glycosylation disor-
ders revealed an additional individual in family F3 with
a homozygous missense mutation in TMEM199 exon 1
(c.92G>C [p.Arg31Pro]). This variant was heterozygous
in both parents (Figures 1 and 2A).324 The American Journal of Human Genetics 98, 322–330, FebruaryWestern blot analysis of TMEM199 was performed in
fibroblasts of affected individuals from families F1 and
F2, and reduced protein levels were observed (Figure 2C,
left). Specificity was demonstrated by detection of
TMEM199-V5 with an anti-TMEM199 antibody after over-
expression of a TMEM199-V5 construct in HeLa cells,
showing a slightly higher molecular weight than endoge-
nous TMEM199 (Figure 2C, right).
TMEM199 (UCSC Genome Browser [GRCh37/hg19],
chr17:26,684,687–26,689,089) contains six exons and en-
codes a protein of 208 amino acids, which includes a
conserved Vma12 domain (Pfam: PF11712) at the C termi-
nus. The Vma12 domain is widespread among eukaryotes,
including Arabidopsis thaliana, and includes two trans-
membrane helices as predicted by the CCTOP server (see
Figure 1 and Web Resources). Interestingly, three of four
mutations alter residues in the N terminus, which seems
to be conserved only in higher eukaryotes. The missense
mutations were variably predicted to be pathogenic by
different prediction programs (Table 1). The Exome Aggre-
gation Consortium (ExAC, see Web Resources) database
showed an absence of all variants except the c.92G>C
variant, which had a very low frequency (5.002e-05).
Individualswithmutations inTMEM199 (Table1) showed
a mild clinical presentation with hypercholesterolemia4, 2016
Table 1. Genotypes and Phenotypes of Families Affected by TMEM199 Deficiency
Family F1 Family F2 Family F3
Individuals (y.o.b.) F1-II2 (1990), F1-II3 (1998) F2-II2 (1974) F3-II1 (1992)
Genotype
Genomic change (chr17) g.26684713C>A g.26684733G>C / g.26687551G>A g.26684785G>C
cDNA change c.20C>A c.40G>C / c.376-1G>A c. 92G>C
Zygosity homozygous compound heterozygous homozygous
Protein change p.Ala7Glu p.Ala14Pro / p.0? p.Arg31Pro
Allele frequency (ExAC) 0 0 / 0 5.002e-05
PhyloP 0.29 3.19 / NA 1.09
SIFT not tolerated tolerated / NA tolerated
PolyPhen-2 (score) possibly damaging (0.609) probably damaging (0.990) / NA probably damaging (0.991)
MutationTaster polymorphism disease causing / NA disease causing
Grantham distance 107 27 / NA 103
Phenotype
Elevated aminotransferases þ þ þ
Elevated alkaline phosphatase þþ þþ þþ
Elevated cholesterol and LDL-C þ þ þ
Steatosis þ þ n.d.
Low ceruloplasmin þ þ þ
Glycosylation profile abnormal N- and O-glycosylation abnormal N-glycosylation abnormal N- and O-glycosylation
Abbreviations are as follows: y.o.b., year of birth; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; n.d., not determined.and elevated low-density lipoprotein cholesterol (LDL-C),
elevated alkaline phosphatase (ALP, bone-derived) and ami-
notransferases (ATs, consisting of aspartate aminotrans-
ferase [AST] and alanine aminotransferase [ALT]). Liver
biopsy showed lipid degeneration and mild steatosis with
minimal fibrosis. In addition, slight abnormalities of copper
metabolism were noted. However, sequencing of ATP7B
(MIM: 606882) for a diagnosis of Wilson disease (WD
[MIM:277900]) failed to detect amutation. Total cholesterol
levelswere in between those of control individuals and indi-
viduals with familial hypercholesterolemia (FH [MIM:
143890]). Inspection of the raw exome-sequencing data
from three individuals revealed no mutations in genes
known to be associated with FH (LDLR [MIM: 606945],
APOB [MIM: 107730], PCSK9 [MIM: 607786]), although
coverage was very poor for exon 1 of these three genes and
for exon 10 of PCSK9. Total cholesterol levels of the parents
were not measured.
The birth and early childhood of brothers F1-II2 and
F1-II3, born 1990 and 1998, respectively, to Greek
consanguineous parents, was unremarkable. During a
routine blood test at fourteen and six years of age, respec-
tively, elevated serum ATs and ALP were noticed (F1-II2:
ALT 54 U/l [normal range, 0–50 U/l], AST 73 U/l [normal
range, 0–50 U/l], ALP 745 U/l [normal range, < 360 U/l];
F1-II3: ALT 210 U/l, AST 246 U/l, ALP 1162 U/l). Gamma-
glutamyl transferase (gGT) and bilirubin levels wereThe Americnormal. A liver ultrasound was normal and liver
biopsy showed steatosis. Their clinical appearance was
unremarkable, and their growth and psychomotor devel-
opment were normal. Isoelectric focusing (IEF) of
transferrin (Tf) showed a type 2 CDG profile. Further
biochemical analysis showed low serum ceruloplasmin
for individual F1-II2 (11.5 mg/dl [normal range,
15–60 mg/dl]) and low-normal ceruloplasmin for individ-
ual F1-II3 (15.6 mg/dl). On suspicion of WD, a slightly
elevated 24 hr urinary copper/creatinine ratio was found
(86.9 and 72.8 mg/g creatinine [normal range, < 60 mg/g
creatinine]). However, Kayser-Fleischer rings were absent,
and genetic testing for ATP7B found no mutations, there-
fore a diagnosis of WD was discarded. Additionally, both
siblings had elevated levels of total cholesterol (F1-II2:
253 mg/dl [normal range, 120–200 mg/dl]; F1-II3:
336 mg/dl) and LDL-C (F1-II2: 188 mg/dl [normal range,
50–130 mg/dl]; F1-II3: 277 mg/dl). Several coagulation
factors were slightly decreased (antithrombin-III, factor
XI, factor XIII, and protein S), but the international
normalized ratio was normal. During subsequent years,
ATs, ALP, and total cholesterol fluctuated from normal
to approximately 1.5 times the upper level of normal.
During their last visit at the ages of 23 and 15 years,
respectively, ALT and AST were within the normal range,
but ALP was still slightly elevated. Lipid levels of individ-
ual F1-II2 had normalized, but for individual F1-II3,an Journal of Human Genetics 98, 322–330, February 4, 2016 325
hypercholesterolemia persisted. Ceruloplasmin levels re-
mained low for both individuals.
Individual F2-II2 is a 41-year-old male with a clinical his-
tory of unexplained elevation of ATs and ALP. His clinical
presentation has been described before.20 During routine
pre-operative investigations for inguinal hernia surgery at
the age of 11, incidentally, elevatedATs andALPwere found
(ALT 190U/l, AST 153U/l, andALP 718U/l). At age 31, after
21 years of unexplained elevated ATs andALP, a liver biopsy
showed steatosis and minimal fibrosis with a hepatic
dry copper weight of 90 mg/g (normal range, <40 mg/g; for
WD, >250 mg/g). Serum ceruloplasmin was decreased
(8.8 mg/dl) and urinary copper levels were normal.
Kayser-Fleischer rings were absent. Based on these para-
meters, WD was discarded as a diagnosis. Additionally,
hypercholesterolemia (204–337 mg/dl) and elevated
LDL-C (182–226 mg/dl) were present. Over the course
of years, ATs regressed to normal (ALT 46–159 U/l, AST
40–110 U/l), but high ALP persisted (365–557 U/l). Meta-
bolic screening showed a type 2 CDG pattern.
Individual F3-II1 is a 23-year-old female born to Greek
parents originating from the same small town. Her
neonatal period was unremarkable. She was first seen by
a clinician at the age of three months with hypotonia,
which persisted during the following years. At the age of
one year old, the diagnosis of benign infantile hypotonia
was made. During early childhood, she also suffered from
psychomotor disability. Brain MRI at the ages of four
years and eleven years was normal. Due to attention
deficit, carbamazepine was started at the age of six years
but was discontinued after two years due to elevation of
her liver enzymes, thought to be drug induced. Over the
course of years, ATs and ALP remained elevated (ALT
36–172 U/l, AST 31–119 U/l, ALP 132–1,528 U/l) with
low-normal ceruloplasmin (17–24 mg/dl). The lipid spec-
trum was normal until the age of five years, but choles-
terol (231–257 mg/dl) and LDL-C (161–171 mg/dl)
increased when she got older. At the age of 13 years, meta-
bolic screening revealed abnormal N- and O-glycosyla-
tion, in agreement with a diagnosis of type 2 CDG.
Subunit analysis of the COG complex failed to detect mu-
tations. Unfortunately, she was lost for follow-up until
2014. In 2014 she was doing well and her ALT, AST, and
ALP were only slightly elevated (58 U/l, 52 U/l, and
132 U/l). Serum ceruloplasmin was low (18 mg/dl) and
hypercholesterolemia persisted.
We performed ultrastructural analysis of liver tissue from
individual F2-II2, directly fixed with 2.5% glutaraldehyde
in 0.1 M phosphate buffer. Hepatocytes were enlarged
with cytoplasmic degeneration. Severe vacuolization was
observed, as well as the presence of large lipid vacuoles,
in agreement with optical microscopy analysis (Figure 2D).
A marked dilation and vesiculation of the Golgi and/or ER
was seen (Figure 2E). In addition, mitochondria featured
fragmented cristae, an altered inner matrix appearing as a
granulo-filamentous material, and sometimes included
electron-dense crystal-like structures (Figure 2F).326 The American Journal of Human Genetics 98, 322–330, FebruaryAll individuals were identified during routine metabolic
diagnostics with abnormal glycosylation of serum Tf in
CDG screening. Tf IEF showed increased disialo- and trisia-
lotransferrin (see Figure 3A and Table S1 for quantification
and ranges), indicating abnormal N-glycosylation. In addi-
tion, IEF of serum apolipoprotein C-III (ApoC-III) for anal-
ysis of mucin-type O-glycosylation showed an abnormal
ApoC-III-1 profile for families F1 and F3 (see Figure 3B
and Table S2 for quantification and ranges).
To gain further insight into the aberrant N-glycan
structures, we performed nanochip-C8 QTOF mass spec-
trometry of the intact Tf protein, which showed an accu-
mulation of incompletely synthesized glycans lacking
galactose and sialic acid for individual F1-II2, in compari-
son to the spectrum of a healthy individual (Figure 3C,
peaks 2–6). Mass spectrometry of total plasma N-glycans
showed a similar pattern, with an increase of glycans lack-
ing galactose and sialic acid (Figure S1). Individuals with
ATP6V0A2 deficiency show very similar glycosylation
abnormalities of Tf, apoC-III, and total plasma N-glycans
(Figures 3A and 3B).11
Next, we labeled sialic acids with alkyne-tagged syn-
thetic sugar analogs, as reported before.21 These sialic
acid precursors (alkyne-tagged mannosamine [ManNAl])
are incorporated into nascent glycoproteins by the cell,
allowing specific detection with fluorescently labeled
azides. The immunofluorescent intensity of the azides is
a marker for Golgi glycosylation efficiency. As in previous
studies, the main pool of labeled glycoproteins located
to the Golgi apparatus in healthy control fibroblasts
(Figure 3E).21 Quantification of the immunofluorescence
signal with TISGolgi, an ImageJ plugin, showed a clear
reduction of absolute Golgi fluorescence intensity in indi-
viduals F1-II2, F1-II3, and F2-II2 (Figures 3D and 3E).
Subsequently, fibroblasts from individual F1-II2 were com-
plemented by transductionwith either a pLenti6.2-GFP-V5
(mock) or a pLenti6.2-TMEM199-V5 (wild-type TMEM199)
vector. As shown in Figure 3F, the overall Golgi fluores-
cence intensity increased after transduction with wild-
type TMEM199 but not with the mock vector. Together,
these data confirm a generalized defect in Golgi processing
of protein-linked glycans due to deficiency of TMEM199.
Our study indicated TMEM199 as the human homolog
of yeast V-ATPase assembly factor Vph2p. In yeast,
V-ATPase assembly factors Vph2p, Vma21p, Pkr1p, and
Vma22p are localized to the ER.17 To define the subcellular
location of TMEM199, a pLenti6.2-TMEM199-V5 plasmid
for expression of C-terminally V5-tagged proteins was
transiently overexpressed in HeLa cells. Imaging was
done with a Leica SP8 (Leica Microsystems) confocal mi-
croscope with 603 water immersion 1.2 NA objective. Fig-
ure 4 shows clear co-localization of V5-tagged TMEM199
with ER-Golgi intermediate compartment (ERGIC) and
coat protein complex I (COPI) vesicle markers. In addition,
partial co-localization was seen with giantin, a Golgi
marker, but not with markers for ER or COPII vesicles.
On the basis of these results, we conclude that TMEM1994, 2016
Figure 3. Glycosylation Abnormalities in
TMEM199-Deficient Individuals
(A) Glycosylation screening by IEF of
serum Tf. The accompanying numbers
represent the total number of sialic acids
in the different protein isoforms. Repre-
sentative N-glycosylation profiles from a
healthy control individual, an ATP6V0A2-
deficient individual, and TMEM199-defi-
cient individuals are shown.
(B) Glycosylation screening by IEF of
serum ApoC-III. ApoC-III has one mucin-
type O-linked glycan with one or two sialic
acids. For normal ranges and quantifica-
tion of Tf-IEF and ApoC-III-IEF, see Tables
S1 and S2.
(C) The nanochip-C8 QTOF mass spec-
trum of a healthy control individual
(left spectrum) and individual F1-II2 (right
spectrum) are shown. Peak 1 (79,556 amu)
represents the intact Tf protein with
two attached complete glycans. Any subse-
quent loss of sialic acid and/or galactose
can be calculated based on the mass differ-
ence with the main peak (i.e., loss of one
sialic acid [purple diamond, peak 2]).
For glycan structural annotation of peaks
1 to 6, see Table S3.
(D–E) Fibroblasts from healthy control
individuals and individuals F1-II2, F1-II3,
and F2-II2 were incubated with ManNAl
for metabolic labeling of sialic acids. The
fluorescent signal indicates incorporation
of sialic acids in glycoconjugates. Three
healthy control fibroblasts were pooled
from experiments performed twice. Scale
bars indicate 75 mm.
(F) Fibroblasts of individual F1-II2 were
transduced with an empty vector or
TMEM199 wild-type construct and incu-
bated with ManNAl, similarly to (D) and
(E). Scale bars indicate 50 mm.predominantly localizes to the ER-to-Golgi region, but not
to the ER.
In parallel with identification of TMEM199 mutations,
we identified mutations in CCDC115 in a cohort of indi-
viduals with abnormal Golgi glycosylation and a storage-
disease-like clinical phenotype including hepatospleno-
megaly, neurological symptoms, elevated ATs, alkaline
phosphatase, and hypercholesterolemia (see the related
paper in this issue of AJHG).22 CCDC115 was predicted
to be homologous to yeast V-ATPase assembly factorThe American Journal of Human GeVma22p. In yeast, Vph2p and
Vma22p are localized to the ER and
cooperatively stabilize the V0 domain
during early assembly of the V-ATPase
in the ER.16,17 The human V-ATPase
proton pump consists of 14 subunits
divided between the membrane-
bound V0 domain and a cytosolic
V1 domain.13 It participates in the
acidification of the secretory pathwayor the extracellular matrix in specialized cells. However,
it has numerous additional functions and associations
with other cellular mechanisms and pathways.13 A few
human disorders involving defects in V-ATPase proteins
are known, including X-linked myopathy with exces-
sive autophagy due to mutations in VMA21 (MIM:
310440),23 renal tubular acidosis with deafness due to mu-
tations in the kidney-specific isoforms ATP6V1B1 (MIM:
267300) or ATP6V0A4 (MIM: 602722),24–26 Zimmerman-
Laband syndrome 2 due to mutations in ATP6V1B2netics 98, 322–330, February 4, 2016 327
Figure 4. Localization of TMEM199
TMEM199 cDNA, compatible with Gateway Technology (Life Technologies), was purchased from Harvard Medical School. HeLa cells
were transfected with FuGENE HD Transfection Reagent (Promega), grown on coverslips coated with poly-L-Lysine (Sigma), and incu-
bated overnight. After permeabilization and fixation, cells were stained with fluorescently labeled antibodies against V5 (green inmerge)
and organellemarkers (magenta inmerge). Shown are representative cells for the V5 antibody, organelle markers, and amerge with DAPI
stain (blue), including a 3-fold magnification. Co-localization is indicated by white in the merged channel. The graphs show the fluo-
rescence intensity profiles along the cross-sections indicated. Scale bars represent 5 mm. Organelle markers used are as follows: anti-V5-
Tag (dilution 1:200, Life Technologies, #R960-25), anti-PDI (1:500, Abcam, #ab3672), anti-ERGIC-53 (1:200, Sigma-Aldrich, #E1031),
anti-Giantin (1:1,000, BioLegend, #prb-114c), anti- BetaCOP (1:1,000, Abcam, #ab2899), and anti-Sec31a (1:500, Sigma-Aldrich,
#HPA005457).
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(MIM: 616455),27 osteopetrosis due to mutations in the
osteoclast-specific V0a3 subunit (MIM: 259700) and cutis
laxa due to mutations in ATP6V0A2.24,28,29 ATP6V0A2 en-
codes the a2 subunit of the V0 domain, which localizes the
V-ATPase complex to the Golgi apparatus, and is the only
core subunit thus far associated with abnormal glycosyla-
tion.11,30 The glycosylation profile seen in ATP6V0A2 defi-
ciency is similar to that of TMEM199 deficiency; however,
the clinical symptoms are clearly different. In addition, a
clear effect of TMEM199mutations was observed on organ-
elle ultrastructure, different from ATP6V0A2 deficiency.12
At the moment, it is difficult to explain the broad
heterogeneity in clinical phenotypes among the dif-
ferent V-ATPase associated diseases. Even mutations in
TMEM199 and CCDC115, whose gene products are prob-
ably interacting in humans, result in different phenotypes.
It seems plausible to attribute these differences to different
functions of the V-ATPase. On the basis of our experiments,
wepropose a role for TMEM199 inGolgi homeostasis. How-
ever, it remains to be investigated whether this function is
mediated through deficient proton transport via an effect
on the V-ATPase or whether TMEM199 exerts additional
roles in ER-to-Golgi transport.
We have shown that prioritization of exome data based
on functional knowledge of abnormal protein glycosyla-
tion can successfully elucidate previously unknown
Golgi homeostasis defects. Protein interaction maps can
be a useful tool for further identification of novel
candidate proteins. During our studies, a protein interac-
tion map of Drosophila melanogaster identified interactions
between CG7071 (the fruit fly TMEM199) and multiple
V-ATPase subunits.31 Recently, an ongoing effort to map
the human interactome reported similar protein-protein
interactions in humans (accessed via BioGRID, see Web
Resources). Such interactomes will be of great benefit for
disease-gene prioritization in cohorts of families with
genetically unsolved cases of type 2 CDGs.
In conclusion,we used comparative genomics to uncover
TMEM199 as a protein involved inGolgi homeostasis,most
likely with at least a partial role in V-ATPase functioning.
TMEM199 deficiency should be considered in individuals
with unexplained mildly elevated serum ATs, elevated
ALP, hepatic steatosis, hypercholesterolemia, and low
serum ceruloplasmin. We suggest screening for abnormal
glycosylation in individuals with these symptoms.Accession Numbers
The accession numbers for the pathogenic variants c.92G>C,
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